NASDAQ:ARQT
Arcutis Biotherapeutics Inc Stock News
$9.20
+0.0800 (+0.88%)
At Close: May 17, 2024
Arcutis to Present at Upcoming Investor Conference
08:00am, Thursday, 01'st Sep 2022
WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-de
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
12:03pm, Monday, 29'th Aug 2022
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA Approval
05:01pm, Tuesday, 05'th Apr 2022
Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psoriasis.
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
11:30am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in i
Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
11:30am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 14'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis to Present at Upcoming Investor Conference
10:30am, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis to Present at Upcoming Investor Conference
10:30am, Wednesday, 02'nd Mar 2022 GlobeNewswire
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
Arcutis to Present at Upcoming Investor Conference
05:30am, Wednesday, 02'nd Mar 2022
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu
Arcutis Biotherapeutics GAAP EPS of -$1.42 beats by $0.18
10:25pm, Tuesday, 22'nd Feb 2022 Seeking Alpha
Arcutis Biotherapeutics press release (ARQT): Q4 GAAP EPS of -$1.42 beats by $0.18.Strong financial position with more than $385M in cash, cash equivalents, and marketable securities.
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immun
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
WESTLAKE VILLAGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2021, and provided a business update.
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
01:00pm, Tuesday, 01'st Feb 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu